2022
Extended versus standard pelvic lymph node dissection yields no difference in 3-year biochemical recurrence rates
Nagaya N, Chua K, Sterling J, Horie S, Kim I. Extended versus standard pelvic lymph node dissection yields no difference in 3-year biochemical recurrence rates. Prostate International 2022, 11: 107-112. PMID: 37409090, PMCID: PMC10318318, DOI: 10.1016/j.prnil.2022.12.005.Peer-Reviewed Original ResearchStandard pelvic lymph node dissectionPelvic lymph node dissectionLymph node dissectionNode-positive patientsNode dissectionAdjuvant treatmentRecurrence rateGleason scoreSubgroup analysisNational Comprehensive Cancer Network guidelinesPSA progression-free survivalAdjuvant androgen deprivation therapyPSA recurrence rateAndrogen deprivation therapyNode-positive diseaseProgression-free survivalGleason score 8Kaplan-Meier analysisAdditional therapeutic benefitBiochemical recurrence ratePositive prostate cancerGleason score 6Time of prostatectomyDeprivation therapyMedian follow
2011
Novel combination markers for predicting progression of nonmuscle invasive bladder cancer
Ha Y, Kim J, Yoon H, Jeong P, Kim T, Yun S, Lee S, Kim G, Choi Y, Moon S, Kim I, Kim W. Novel combination markers for predicting progression of nonmuscle invasive bladder cancer. International Journal Of Cancer 2011, 131: e501-e507. PMID: 22025348, DOI: 10.1002/ijc.27319.Peer-Reviewed Original ResearchConceptsNonmuscle invasive bladder cancerInvasive bladder cancerMethylation-specific polymerase chain reactionBladder cancerNMIBC progressionMultivariate Cox regression analysisPredictive combinationCox regression analysisKaplan-Meier estimatesMRNA expression levelsBest predictive combinationMedian followRUNX3 promoter methylationIntravesical therapyPrognostic effectSpecific polymerase chain reactionSubgroup analysisEffect of RUNX3Prognostic markerReal-time PCRHigh riskCombination markersPatientsMRNA expressionProgression